Inhibition of p-STAT3 with C188-9, which is currently undergoing clinical trials for cancer treatment (45), reduces PD-L1 expression levels in tumor cells, enhances CD8+ T cell infiltration, and inhibits tumor growth. Here, STAT3 is linked to neoplasm.